Day 1 | Connecting Global Oligonucleotide Developers with Trusted Chinese CDMO Partners

🔬 Hello to all colleagues involved in oligonucleotide drug research,
Today, I’m excited to announce a new venture.
We have launched a specialized consulting and technical-matching platform that connects overseas oligonucleotide (Oligo) drug developers and research institutions with reliable, high-quality, and cost-competitive CDMO partners in China—quickly, accurately, and with minimal risk.
Oligonucleotide therapeutics such as ASOs, siRNAs, mRNAs, AOCs (antibody-oligo conjugates), POCs (peptide-oligo conjugates), and GalNAc conjugates are already demonstrating commercial success, and clinical demand is accelerating.
However, many overseas teams face challenges such as:
・Difficulty evaluating a CDMO’s technical capabilities and quality systems (purity, yield)
・Limited visibility into impurity analysis and N-impurity (e.g., N-1, N-2, N-3) identification capabilities
・Uncertainty about regulatory compliance (GMP, FDA, EMA)
・Communication barriers due to language, time zones, and documentation differences
Meanwhile, Chinese CDMOs offer significant advantages:
・Strong cost competitiveness
・Fast response times
・Extensive IND and clinical manufacturing experience
・Integrated capabilities from amidite → API → intermediates → final formulation
By bridging this information gap, oligonucleotide projects can proceed faster and with lower risk.
On LinkedIn, I will continue sharing:
・Practical insights for selecting CDMOs
・Real examples from scale-up and quality management
・Common pitfalls in international project execution
・The current capabilities and evolution of Chinese CDMOs
・If you are looking for reliable information or would like to discuss potential collaborations, please feel free to reach out.

Note:
・Our service is free for overseas companies and research institutions; it is supported by CDMO referral fees.
・Our company website is currently under construction; we will announce its launch soon.
Day 1—let’s get started.